A new GLP-1 pill helped people with type 2 diabetes lose more weight than oral semaglutide.
Participants lost up to 8% of body weight during a one-year phase 3 trial.
Eli Lilly developed the drug, called orforglipron.
It lowers blood sugar, slows digestion, and reduces appetite.
Patients can take it without fasting.
More than 1,500 adults joined the international study.
Orforglipron also reduced average glucose levels more effectively than semaglutide.
However, more patients stopped treatment because of gastrointestinal side effects.
Experts see strong potential for easier, cheaper therapy without injections.
Researchers still need long-term safety and cardiovascular data.
They expect potent oral incretin drugs to reshape diabetes care.
